SG Americas Securities LLC Sells 18,033 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

SG Americas Securities LLC reduced its position in shares of Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) by 49.8% during the 1st quarter, HoldingsChannel.com reports. The fund owned 18,194 shares of the biotechnology company’s stock after selling 18,033 shares during the quarter. SG Americas Securities LLC’s holdings in Blueprint Medicines were worth $1,162,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale grew its holdings in Blueprint Medicines by 4.6% during the first quarter. DekaBank Deutsche Girozentrale now owns 25,150 shares of the biotechnology company’s stock worth $1,636,000 after purchasing an additional 1,100 shares during the period. Peregrine Capital Management LLC boosted its stake in shares of Blueprint Medicines by 2.6% during the 1st quarter. Peregrine Capital Management LLC now owns 126,868 shares of the biotechnology company’s stock worth $8,104,000 after acquiring an additional 3,199 shares during the period. Comerica Bank increased its holdings in shares of Blueprint Medicines by 13.4% during the 1st quarter. Comerica Bank now owns 109,049 shares of the biotechnology company’s stock worth $7,366,000 after acquiring an additional 12,927 shares during the last quarter. EFG Asset Management North America Corp. raised its stake in Blueprint Medicines by 21.3% in the 1st quarter. EFG Asset Management North America Corp. now owns 136,691 shares of the biotechnology company’s stock valued at $8,730,000 after acquiring an additional 23,976 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in Blueprint Medicines by 370.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 274,707 shares of the biotechnology company’s stock valued at $17,548,000 after purchasing an additional 216,374 shares during the last quarter. Institutional investors and hedge funds own 99.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on BPMC shares. Stifel Nicolaus cut their target price on shares of Blueprint Medicines from $98.00 to $90.00 in a research note on Friday, July 1st. Wells Fargo & Company assumed coverage on Blueprint Medicines in a report on Monday, June 27th. They set an “underweight” rating and a $40.00 price objective for the company. JMP Securities reiterated a “buy” rating and set a $152.00 target price on shares of Blueprint Medicines in a research note on Thursday, June 9th. Piper Sandler reduced their price target on Blueprint Medicines from $84.00 to $65.00 and set a “neutral” rating for the company in a research note on Wednesday, May 18th. Finally, StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Monday, May 9th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $88.86.

Blueprint Medicines Stock Down 1.8 %

NASDAQ BPMC opened at $51.06 on Friday. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of -4.70 and a beta of 0.99. Blueprint Medicines Co. has a twelve month low of $43.46 and a twelve month high of $117.86. The stock has a fifty day simple moving average of $53.90 and a 200 day simple moving average of $62.14.

Blueprint Medicines (NASDAQ:BPMCGet Rating) last announced its earnings results on Tuesday, May 3rd. The biotechnology company reported ($1.79) EPS for the quarter, meeting the consensus estimate of ($1.79). Blueprint Medicines had a negative return on equity of 35.24% and a negative net margin of 293.97%. The business had revenue of $62.70 million for the quarter, compared to analysts’ expectations of $39.98 million. During the same period in the prior year, the business posted ($1.72) earnings per share. The firm’s revenue was up 190.3% on a year-over-year basis. Research analysts expect that Blueprint Medicines Co. will post -7.59 earnings per share for the current fiscal year.

Insider Transactions at Blueprint Medicines

In related news, insider Percy H. Carter sold 1,908 shares of the business’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $59.76, for a total transaction of $114,022.08. Following the transaction, the insider now owns 28,685 shares in the company, valued at approximately $1,714,215.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.34% of the company’s stock.

Blueprint Medicines Profile

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

See Also

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMCGet Rating).

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.